This comes at a critical juncture for VTAMA ®, a drug that has demonstrated blockbuster potential through Organon's $1.2 billion acquisition from Dermavant Sciences yet could face imminent ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. If it goes ...

R&D Head Juan Camilo Arjona Ferreira emphasized the potential of Vtama, which received FDA approval for atopic dermatitis in ...

Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA ® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just ...